SAN RAFAEL, Calif.,
April 21, 2020 /PRNewswire/ --
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced the
appointment of C. Greg Guyer, Ph.D.,
to Chief Technical Officer, Executive Vice President of Global
Manufacturing and Technical Operations. Effective
May 4, Dr. Guyer will succeed
Robert Baffi, Ph.D., President,
Global Manufacturing and Technical Operations, who will remain at
BioMarin full-time as a Special Advisor to the Chairman and CEO for
the remainder of the year as he moves toward retirement. In 2021,
Dr. Baffi will continue at BioMarin in a part-time capacity.
The culmination of this multi-year succession plan ensures
continuity during the transition.
"Robert's indispensable contributions over the past two decades
are foundational to our business and have been integral to the
success of BioMarin as a whole. Beyond establishing the
technical operations infrastructure that supports our commercial
production and distribution demands globally, he had the foresight
to build our gene therapy manufacturing capabilities providing a
competitive advantage to BioMarin in this emerging technology,"
said Jean-Jaques Bienaimé, Chairman and Chief Executive
Officer. "He has developed a world class organization,
recruited an outstanding team, built three manufacturing
facilities, and has been the tactician in the development of our
innovative and successful CMC strategies. The Board and I are
grateful for Robert's leadership and his ongoing commitment to
BioMarin. After leading the recruitment effort for his
successor, Robert will continue to serve as a full-time advisor to
ensure a seamless transition, and he will also assist with the
ongoing regulatory review of valoctocogene roxaparvovec and the
preparation of the vosoritide marketing applications."
"I am thrilled to welcome Greg to the leadership team. His
organizational experience brings enormous benefit to the
operational excellence goals of BioMarin as we continue our growth
into profitability," said Mr. Bienaimé. "Greg's diverse
experiences in the production of monoclonal antibodies and vaccines
along with his technical skills from formulation development to
fill finish will enable him to provide technical oversight over our
full spectrum of operations."
"Greg is an ideal successor to lead BioMarin's Global
Manufacturing and Technical Operations and I look forward to
collaborating with him during the transition. His depth and
breadth of experience go well beyond just technical
capabilities. His scientific background and experience at the
FDA provide an additional and unique dimension to the way he will
contribute to BioMarin's ongoing success," said Dr. Baffi. "I
am proud of BioMarin's leadership in the development of complex
proteins and viral vectors and am confident that Greg will build
upon the solid foundation that we have created over the past 20
years."
"It is an exciting time to join the BioMarin team. I was
drawn to the company not only because of its potential for growth
and pioneering spirit, but also to its world-class technical and
manufacturing capabilities," said Dr. Guyer, soon to be Chief
Technical Officer, Executive Vice President of Global Manufacturing
and Technical Operations at BioMarin. "The unwavering passion for
patients with rare diseases has been palpable in all my
interactions with JJ, Robert and the entire leadership team.
This opportunity to contribute to such a noble cause and to work
with a world-class team is highly motivating."
Most recently, Dr. Guyer was the Senior Vice President,
Operations at Bristol Myers Squibb where he led all internal
pharmaceutical and biologics manufacturing and packaging sites, all
external manufacturing relationships, Manufacturing Sciences and
Technology and administrative Facilities and Engineering for Global
Research and Development corporately. He supported global
sales of more than $20 billion
annually while leading over 4,000 employees globally. Prior
to Bristol Myers Squibb, Dr. Guyer worked at Merck for 21 years
where he was responsible for Global Quality before gaining
operations experience with plant management and enterprise resource
planning. He started his career working at FDA in the lab and
over 10 years rose to Division Director for Generic Drugs.
About BioMarin
BioMarin is a global biotechnology company that develops and
commercializes innovative therapies for patients with serious and
life-threatening rare and ultra-rare genetic diseases. The
company's portfolio consists of six commercialized products and
multiple clinical and pre-clinical product candidates. For
additional information, please visit www.biomarin.com.
Information on such website is not incorporated by reference into
this press release.
Forward-Looking Statement
This press release contains forward-looking statements about the
business prospects of BioMarin Pharmaceutical Inc. (BioMarin),
including, without limitation, statements about: Dr. Guyer's
appointment and his anticipated contributions to the company's
success, Dr. Baffi's continued employment, and the Company's
ability to execute on its manufacturing and technical operations
strategies. These forward-looking statements are predictions and
involve risks and uncertainties such that actual results may differ
materially from these statements. These risks and uncertainties
include, among others: Dr. Guyer commencing employment as
anticipated, possible complications associated with the leadership
transition within the Technical Operations organization, and those
factors detailed in BioMarin's filings with the Securities and
Exchange Commission (SEC), including, without limitation, the
factors contained under the caption "Risk Factors" in BioMarin's
Quarterly Report on Form 10-K for the year ended December 31, 2019 as such factors may be updated
by any subsequent reports. Stockholders are urged not to place
undue reliance on forward-looking statements, which speak only as
of the date hereof. BioMarin is under no obligation, and expressly
disclaims any obligation to update or alter any forward-looking
statement, whether as a result of new information, future events or
otherwise.
BioMarin® is a registered trademark of BioMarin Pharmaceutical
Inc.
Contact:
|
Investors:
|
Media:
|
Traci
McCarty
|
Debra
Charlesworth
|
BioMarin
Pharmaceutical Inc.
|
BioMarin
Pharmaceutical Inc.
|
(415)
455-7558
|
(415)
455-7451
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biomarin-appoints-global-pharmaceutical-veteran-c-greg-guyer-phd-to-chief-technical-officer-executive-vice-president-of-global-manufacturing-and-technical-operations-effective-may-4-301044126.html
SOURCE BioMarin Pharmaceutical Inc.